Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes

Blood Cancer J. 2021 Nov 13;11(11):180. doi: 10.1038/s41408-021-00551-y.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Anthracyclines / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cytarabine / administration & dosage
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Registries*
  • Remission Induction

Substances

  • Anthracyclines
  • Cytarabine